ExploreWatchlistsPricing
  1. JP-listed companies
  2. RaQualia Pharma Inc.
  3. Financials
  4. Revenue growth (%)

RaQualia Pharma Inc. (4579)

Market cap
¥22.3B
P/E ratio
-331.8x
Rakuoria Drug Discovery develops new pharmaceutical compounds through early-stage research and clinical trials, then licenses them to major pharmaceutical companies for revenue.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndRevenue growth (%) YoY (%)
Dec 31, 202528.1-55.76%
Dec 31, 202463.5-282.07%
Dec 31, 2023-34.8-782.00%
Dec 31, 20225.1-96.61%
Dec 31, 2021150.7-530.87%
Dec 31, 2020-35-127.17%
Dec 31, 2019128.7-370.80%
Dec 31, 2018-47.5-146.96%
Dec 31, 2017101.2-73.68%
Dec 31, 2016384.7-7145.79%
Dec 31, 2015-5.5-83.14%
Dec 31, 2014-32.4-104.73%
Dec 31, 2013685.5-815.84%
Dec 31, 2012-95.8

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat